• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fortress Biotech Inc.

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBIO alert in real time by email
    SC 13G 1 p24-3018sc13g.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    Fortress Biotech, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    34960Q307

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 34960Q307

    13GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,734,854 shares of Common Stock issuable upon the exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,734,854 shares of Common Stock issuable upon the exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,734,854 shares of Common Stock issuable upon the exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.0%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 34960Q307

    13GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Fortress Biotech, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.

     

    Item 2(a). NAME OF PERSON FILING:

     

     

    This statement is filed by Highbridge Capital Management, LLC (“Highbridge” or the “Reporting Person”), a Delaware limited liability company and the investment adviser to certain funds and accounts (the “Highbridge Funds”), with respect to the shares of Common Stock (as defined in Item 2(d) below) underlying warrants directly held by the Highbridge Funds.

     

      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:

     

      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      34960Q307

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,

     

     

    CUSIP No. 34960Q307

    13GPage 4 of 6 Pages

     

      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:__________________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.

     

    The percentages set forth herein are calculated based upon 27,563,494 shares of Common Stock reported to be outstanding as of September 25, 2024 as reported in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 27, 2024, and assumes the exercise of the warrants held by the Highbridge Funds.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein.  Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Common Stock.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

    CUSIP No. 34960Q307

    13GPage 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      The Reporting Person hereby makes the following certification:
     

     

    By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

       

     

    CUSIP No. 34960Q307

    13GPage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: October 25, 2024

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC

     

         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

    Get the next $FBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FBIO

    DatePrice TargetRatingAnalyst
    3/15/2024$10.00Buy
    ROTH MKM
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      9/25/24 4:45:04 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/15/24 4:05:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/12/24 8:42:21 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    SEC Filings

    See more
    • Fortress Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Fortress Biotech, Inc. (0001429260) (Filer)

      6/23/25 8:55:54 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - Fortress Biotech, Inc. (0001429260) (Filer)

      6/5/25 4:15:27 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Fortress Biotech Inc.

      10-Q - Fortress Biotech, Inc. (0001429260) (Filer)

      5/15/25 4:34:46 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Fortress Biotech with a new price target

      ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

      3/15/24 7:18:10 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

      Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00

      8/4/22 7:17:35 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Fortress Biotech with a new price target

      Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously

      4/20/21 8:28:52 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

      In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data support a novel combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug Designation to Mustang for MB-108 for the treatment of malignant glioma WORCESTER, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical b

      7/7/25 8:30:55 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

      SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi™ for the treatment of moderate-to-severe papulopustular rosacea in adults will be presented at the Society of Dermatology Physician Associates (SDPA) 2025 Summer Dermatology Conference taking place June 25-29 in Washington

      6/20/25 8:30:33 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Jin David was granted 5,000 shares, increasing direct ownership by 0.40% to 1,245,893 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      4/1/25 4:20:16 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lobell J Jay was granted 49,383 shares, increasing direct ownership by 43% to 165,075 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:28:30 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Klein Dov was granted 49,383 shares, increasing direct ownership by 92% to 102,783 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:20:17 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fortress Biotech Inc.

      SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

      10/25/24 10:15:19 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

      SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

      9/25/24 4:45:18 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

      SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

      2/14/24 4:51:41 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

      UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

      5/13/25 4:15:51 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care